


Experience of Faropenem for the management of urinary tract infection

- ⚡ Urinary tract infections (UTIs) are among the most common bacterial infections, with increasing resistance due to extended-spectrum β -lactamase (ESBL)-producing organisms.
- ⚡ Faropenem, an oral penem antibiotic, has emerged as an effective alternative to conventional therapies owing to its broad-spectrum activity, resistance stability, and favorable safety profile. Real-world evidence from India highlights the growing acceptance of Faropenem by urologists for managing complicated UTIs (cUTIs).

Study Design		Real-world cross-sectional survey of urologists	
Participants	Year	Intervention	Outcome
391 Indian urologists across multiple states	2020	Use of Faropenem in complicated UTI (cUTI) management	100% rated Faropenem effective (66.4% very effective + 33.6% extremely effective); 66.4% supported as step-down therapy; 68.5% considered safe; 22.2% rated excellent safety profile

Urologists' clinical experience with Faropenem in cUTI management



This survey-based real-world data from 391 Indian urologists showed that faropenem is effective and well-tolerated for UTIs, including complicated cases and as step-down therapy, with strong activity against ESBL and other cephalosporin-resistant pathogens.

Ref.: IP Journal of Urology, Nephrology & Hepatology Science October-December 2020;3(4):77-81

Brought to you by




Drug Review

Antimicrobial resistance

- Antimicrobial resistance (AMR) has been prioritized by the World Health Organization (WHO) as one of the top 10 global public health threats facing humanity.²
- Resistance to beta-lactams is an alarming and growing phenomenon and, in turn, a public health challenge. Following are the mechanisms of resistance³ :
 - Inactivation by the production of beta-lactamases.
 - Decreased penetration to the target site (e.g., the resistance of *Pseudomonas aeruginosa*).
 - Alteration of target site Penicillin Binding Proteins (PBPs) (e.g., penicillin resistance in *pneumococci*).
 - Efflux from the periplasmic space through specific pumping mechanisms.

The key distinguishing features of faropenem⁴⁻⁷

Faropenem- a penem with unique chemical structure



Time, concentration and oxygen dependent **bactericidal effect** against **Aerobic, Anaerobic, Gram-positive & Gram-negative** bacteria.

Faropenem has shown lower MICs (Minimum Inhibitory Concentrations) than other beta-lactam antibiotics against certain bacteria.

	Bacteria	Faropenem			Amox - clav		Cefuroxime		Imipenem	
		MIC ₅₀	MIC ₉₀	Range	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀
Gram (+ve)	<i>Staphylococcus aureus</i> (MS)	0.12	0.12	0.03–0.5	1	2	1	2	≤ 0.5	≤ 0.5
	<i>S. aureus</i> (MR)	>32	>32	0.12–>32	8	16	>32	>32	32	32
	<i>Staphylococcus epidermidis</i> (All)	0.12	0.5	0.06 –>128	1	8	0.5	16	0.016	16
	<i>S. epidermidis</i> (MS)	0.12	0.5	0.06 – 4	1	2	0.5	1	0.016	0.016
	<i>Streptococcus pyogenes</i>	0.03	0.03	≤ 0.015 – 0.06	0.03	0.03	≤ 0.015	≤ 0.015	≤ 0.008	≤ 0.008
Gram (-ve)	<i>Streptococcus pneumoniae</i>	0.008	0.25	≤ 0.004 – 2	0.03	0.5	≤ 0.12	4	≤ 0.5	≤ 0.5
	<i>Escherichia coli</i>	0.5	1	0.12 – 32	4	16	4	8	≤ 0.5	≤ 0.5
	<i>Haemophilus influenzae</i>	0.25	1	≤ 0.004 – 4	0.5	1	0.5	2	1	4
	<i>H. influenzae</i> (BLN)	0.25	1	≤ 0.004 – 4	0.5	1	0.5	2	1	2
	<i>Klebsiella pneumoniae</i>	0.5	2	0.25 –>32	2	8	4	>32	0.25	1

Ref: 1. Chimura T, Kaneko N, Hayashi Y, Funayama T, Numazaki M, Oda T, Murayama K, Morisaki N, Hirayama T, Sato F, Akatsuka K. [Clinical studies of faropenem in the field of obstetrics and gynecology]. *Jpn J Antibiot.* 1999 Jul;52(7):504-10. Japanese. PMID: 10516930 | 2. 10 global health issues to track in 2021, World Health Organization Newsroom (24 Dec 2020) | 3. Phenotypic Characterization and Antibiotic Resistance Patterns of Extended-Spectrum β -Lactamase- and AmpC β -Lactamase-Producing Gram-Negative Bacteria in a Referral Hospital, Saudi Arabia, Ibrahim ME, Abbas M, Al-Shahrai AM, Elamin BK. *Can J Infect Dis Med Microbiol* | 4. Dalhoff A, Janjic N, Echols R. Redefining penems. *Biochem. Pharmacol.* 71(7), 1085–1095 (2006) | 5. Dalhoff A, Nasu T, Okamoto K. β -lactamase stability of Faropenem. *Chemotherapy* 49(5), 229–236 (2003) | 6. Faropenem: review of a new oral penem, Kristen N Schurek, Ryan Wiebe, James A Karlowsky, Ethan Rubinstein, Daryl J Hoban and George G Zhanel, *Expert Rev. Anti Infect. Ther.* 5(2), (2007) | 7. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of faropenem demonstrated by studies of time–kill kinetics and post-antibiotic effect. *J. Antimicrob. Chemother.* 39(3), 415–418 (1997) |